We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+1.18%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$704K
(+0.28%)
Cap. Flow
+$4.85M
Cap. Flow
% of AUM
1.91%
Top 10 Holdings %
Top 10 Hldgs %
43.68%
Holding
90
New
20
Increased
18
Reduced
11
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$9.28M |
| 2 |
Takeda Pharmaceutical
TAK
|
+$9.02M |
| 3 |
SIEN
Sientra, Inc.
SIEN
|
+$8.62M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$8.05M |
| 5 |
Humana
HUM
|
+$7.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$13.8M |
| 2 |
Gilead Sciences
GILD
|
+$10.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$9.55M |
| 4 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$5.99M |
| 5 |
Evolent Health
EVH
|
+$5.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.04% |
| 2 | Technology | 6.14% |
| 3 | Industrials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
VistaGen Therapeutics
VTGN
$9.89M
| – | – |
-12,031
| Closed | -$462K |
|
77
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| – | – |
-40,700
| Closed | -$3.73M |
|
|
KA
78
CALL
DELISTED
Kineta, Inc. Common Stock
KA
| – | – |
-933
| Closed | -$165K |
|
|
IMGN
79
CALL
DELISTED
Immunogen Inc
IMGN
| – | – |
-86,800
| Closed | -$235K |
|
|
IMGN
80
DELISTED
Immunogen Inc
IMGN
| – | – |
-184,440
| Closed | -$500K |
|
|
VRAY
81
DELISTED
ViewRay, Inc.
VRAY
| – | – |
-96,580
| Closed | -$714K |
|
|
SIOX
82
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| – | – |
-181,664
| Closed | -$1.93M |
|
|
TVTY
83
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| – | – |
-77,929
| Closed | -$1.37M |
|
|
LMNX
84
DELISTED
Luminex Corp
LMNX
| – | – |
-121,017
| Closed | -$2.79M |
|
|
AGN
85
DELISTED
Allergan plc
AGN
| – | – |
-18,263
| Closed | -$2.67M |
|
|
ARRY
86
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-16,447
| Closed | -$401K |
|
|
BHVN
87
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-7,479
| Closed | -$385K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Endurant Capital Management held 90 positions worth $254M, up 0.28% from $253M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management's Q2 2019 filing shows 20 new, 18 increased, 11 reduced and 40 closed positions. Its largest new stake was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M. The largest sale was Icon, an estimated $13.8M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 74% a quarter earlier, followed by Technology and Industrials.
- Endurant Capital Management's largest Q2 2019 buy was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.
- Endurant Capital Management added most to Takeda Pharmaceutical in Q2 2019, an estimated $9.02M increase.
- Endurant Capital Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $9.55M.
- Endurant Capital Management fully exited Icon in Q2 2019, selling an estimated $13.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $254M portfolio in Q2 2019.
- Endurant Capital Management opened 20 new positions and closed 40 in Q2 2019.
- Endurant Capital Management's portfolio value rose 0.28% quarter-over-quarter to $254M.
Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.